5 FDA Decisions to Watch For: Q2 2026

Several regulatory decisions expected in 2026 may introduce new treatment options across high-impact areas in primary care, including type 2 diabetes, obesity, hypertension, smoking cessation, dermatology, and attention-deficit/hyperactivity disorder (ADHD). These investigational therapies span both first-in-class mechanisms and novel formulations of existing drug classes, with potential implications for prescribing patterns and patient adherence.